Thammineedi Subramanyeshwar Rao, Patnaik Sujit Chyau, Nusrath Syed
Department of Surgical Oncology, Basavatarakam Indo American Cancer Hospital and Research Institute, Hyderabad, India.
Indian J Surg Oncol. 2020 Dec;11(4):615-624. doi: 10.1007/s13193-020-01191-7. Epub 2020 Sep 1.
Surgery is the mainstay of esophageal cancer. However, esophagectomy is a major surgical trauma on a patient with high morbidity and mortality. The intent of minimally invasive esophagectomy (MIE) is to decrease the degree of surgical trauma and perioperative morbidity associated with open surgery, and provide faster recovery and shorter hospital stay with the equivalent oncological outcome. It also allows for lesser pulmonary morbidity, less blood loss, less pain, and a better quality of life. MIE is safe and effective but has a steep learning curve with high technical expertise. Recently, it is increasingly accepted and adopted all over the globe. In this article, we discuss the safety, efficacy, short-term, and oncological outcomes of thoracoscopic- and laparoscopic-assisted minimally invasive esophagectomy and robotic surgery compared with open esophagectomy with a special focus on the Indian perspective.
手术是食管癌治疗的主要手段。然而,食管切除术是一种对患者造成重大手术创伤的操作,其发病率和死亡率都很高。微创食管切除术(MIE)的目的是降低与开放手术相关的手术创伤程度和围手术期发病率,并在肿瘤学效果相当的情况下实现更快的恢复和更短的住院时间。它还能减少肺部并发症、减少失血、减轻疼痛,并提高生活质量。MIE安全有效,但技术要求高,学习曲线陡峭。最近,它在全球范围内越来越被接受和采用。在本文中,我们将讨论胸腔镜和腹腔镜辅助微创食管切除术以及机器人手术与开放食管切除术相比的安全性、有效性、短期和肿瘤学结果,并特别关注印度的情况。